考虑出售中国业务？GE医疗回应市场传闻

Core Viewpoint - GE Healthcare is reportedly exploring options to sell its stake in the Chinese market due to declining revenues, rising tariff costs, and increasing competition from local companies [1][5]. Group 1: Financial Performance - GE Healthcare's global revenue for the year reached $19.7 billion, a slight increase of 1% year-on-year, while adjusted EBIT was $3.2 billion [1]. - In China, GE Healthcare's revenue fell to $2.36 billion, marking a significant decline of 15%, the largest drop since the company became independent in 2023 [1]. Group 2: Market Competition - In the first half of 2025, Siemens Healthineers achieved revenue of €11.57 billion (approximately $13.39 billion), a 7% year-on-year increase, while GE Healthcare's revenue was $9.78 billion, up 3% [2]. - Siemens Healthineers was the only major player to see growth in the Chinese market, with a 2.4% increase, while GE Healthcare and Philips experienced declines of 2% and 11%, respectively [2]. - Local companies like United Imaging, Mindray, and Neusoft are rapidly gaining market share, employing integrated strategies to challenge foreign giants [2]. Group 3: Technological Advancements - Chinese companies are making significant strides in high-end medical equipment, with United Imaging and Neusoft receiving approval for photon-counting CT devices, marking a leap in next-generation CT technology [3][4]. - The photon-counting CT market is projected to reach approximately $2 billion globally by 2025, with local firms establishing a dual-leader position in the market [4]. Group 4: Strategic Implications - The potential sale of GE Healthcare's Chinese business could signal a significant strategic shift for multinational companies operating in China, reflecting the increasing challenges posed by local competitors [5].